High-dimensional quantum information processing with linear optics

Quantum information processing (QIP) is an interdisciplinary field concerned with the development of computers and information processing systems that utilize quantum mechanical properties of nature to carry out their function. QIP systems have become vastly more practical since the turn of the century. Today, QIP applications span imaging, cryptographic security, computation, and simulation (quantum systems that mimic other quantum systems). Many important strategies improve quantum versions of classical information system hardware, such as single photon detectors and quantum repeaters. Another more abstract strategy engineers high-dimensional quantum state spaces, so that each successful event carries more information than traditional two-level systems allow. Photonic states in particular bring the added advantages of weak environmental coupling and data transmission near the speed of light, allowing for simpler control and lower system design complexity. In this dissertation, numerous novel, scalable designs for practical high-dimensional linear-optical QIP systems are presented. First, a correlated photon imaging scheme using orbital angular momentum (OAM) states to detect rotational symmetries in objects using measurements, as well as building images out of those interactions is reported. Then, a statistical detection method using chains of OAM superpositions distributed according to the Fibonacci sequence is established and expanded upon. It is shown that the approach gives rise to schemes for sorting, detecting, and generating the recursively defined high-dimensional states on which some quantum cryptographic protocols depend. Finally, an ongoing study based on a generalization of the standard optical multiport for applications in quantum computation and simulation is reported upon. The architecture allows photons to reverse momentum inside the device. This in turn enables realistic implementation of controllable linear-optical scattering vertices for carrying out quantum walks on arbitrary graph structures, a powerful tool for any quantum computer. It is shown that the novel architecture provides new, efficient capabilities for the optical quantum simulation of Hamiltonians and topologically protected states. Further, these simulations use exponentially fewer resources than feedforward techniques, scale linearly to higher-dimensional systems, and use only linear optics, thus offering a concrete experimentally achievable implementation of graphical models of discrete-time quantum systems

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort (Nature, (2020), 583, 7814, (90-95), 10.1038/s41586-020-2265-1)

An amendment to this paper has been published and can be accessed via a link at the top of the paper

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc